Recent Updates
Recently added Catalysts
TLX Negative Sentiment Score: 25/100

Telix Pharmaceuticals Ltd. Class Action: Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX

Key Takeaway: Levi & Korsinsky, LLP has announced a class action lawsuit against Telix Pharmaceuticals Ltd. for alleged securities fraud affecting investors between February 21, 2025, and August 28, 2025. The lawsuit claims that the company made false statements regarding its progress with prostate cancer therapies and the quality of its supply chain. Investors have until January 9, 2026, to request to be appointed as lead plaintiffs. The firm emphasizes there are no costs for class members to participate in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges securities fraud that could significantly impact investor confidence.
  • Claims of overstated progress on therapeutic candidates and quality of supply chain raise serious concerns about Telix's operations.
  • Investors are facing potential financial losses due to the fraudulent actions being alleged.

Full Press Release Details

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:
TLX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants materially overstated the progress Telix had made with regard to prostate cancer therapeutic candidates; (2) defendants materially overstated the quality of Telix’s supply chain and partners; and (3) as a result, defendants’ statements about Telix’s business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHAT'S NEXT? If you suffered a loss in Telix Pharmaceuticals Ltd. during the relevant time frame, you have until January 9, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the Telix Pharmaceuticals lawsuit about?

The lawsuit claims that Telix Pharmaceuticals misled investors regarding its progress and supply chain.

Who can join the lawsuit against Telix Pharmaceuticals?

Investors affected by the alleged fraud between February 21, 2025, and August 28, 2025, may join.

What is the deadline to become a lead plaintiff?

The deadline to request lead plaintiff status is January 9, 2026.

Will it cost me to participate in the lawsuit?

There are no out-of-pocket costs for class members to participate or seek compensation.

Why choose Levi & Korsinsky for this case?

Levi & Korsinsky has a strong track record in securities litigation and has secured substantial recoveries.

Last updated: Dec 18, 2025